Drugs Made In America Acquisition (DMIIR) Income towards Parent Company (2025)
Drugs Made In America Acquisition (DMIIR) reported Income towards Parent Company of $4.6 million for Q4 2025, up 10041.88% on a QoQ basis from -$46158.0 in Q3 2025.
Drugs Made In America Acquisition (DMIIR) has 1 years of Income towards Parent Company data on file, last reported at $4.6 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - |
| 2 | Berto Acquisition | 316.66 Mn | 316.66 Mn | - |
| 3 | Centurion Acquisition | 311.94 Mn | 311.94 Mn | - |
| 4 | Churchill Capital Corp IX | 311.36 Mn | 311.36 Mn | - |
| 5 | Agriculture & Natural Solutions Acquisition | 301.94 Mn | 301.94 Mn | - |
| 6 | Siddhi Acquisition Corp (Cayman Islands) | 286.76 Mn | 286.76 Mn | - |
| 7 | Bold Eagle Acquisition | 276.06 Mn | 276.06 Mn | - |
| 8 | Cartesian Growth Corp III | 270.68 Mn | 270.68 Mn | - |
| 9 | Oyster Enterprises II Acquisition | 266.84 Mn | 266.84 Mn | - |
| 10 | Drugs Made In America Acquisition | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | -46,158.00 |